Stocks›Healthcare›ABBV

ABBV

AbbVie Inc.

NYSEResearch view

AbbVie Inc. operates in the Pharmaceutical Preparations industry.

$266.69+0.35%

Oct 6 close · 1D EOD · Databento

HealthcarePharmaceutical PreparationsMega-capSEC EDGAR FY 2025-12-31

What happened

Daily closes · dots are Wire stories

2 stories have a settled receipt so far (2 on the Wire). The record starts speaking at three.

What’s next

Expected around late October, going by its own filing history. The company has not announced a date yet. Its matching report came Oct 31, 2025 and Oct 30, 2024, during the session.

Last report

Jul 31, 2026−2.51%

during the session

Last 4, next close

median 3.46% either way

up 1 of 4

Every report since 2024 →Earnings calendar →

DateEventSourceNext close

Sep 3AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple MyelomaPR NewswirePR Newswire−0.58%
Sep 3AbbVie Completes Acquisition of Apogee TherapeuticsPR NewswirePR Newswire−0.58%
Jul 31Earnings release, during the session · 8-KSEC EDGARSEC EDGAR ↗−2.51%

Next close = the first close after the event against the close before it. Prior-session closes only; not a call, not advice.

What happened · big days

23 big days in a year, and what we hold on each

A big day is a close more than 2.84% from the one before, three times ABBV’s median day (0.95%). On 10 of the 23, its peer group moved the same way at least half as far. We show what we hold. We never name a cause.

every other trading daya big day, numbered in the list below±2.84%Hover a bar for its day. Click a big day to open it.

Shaded: since our stories began, Jun 10. Tap a bar for its day.

#DayABBVWhat we hold that dayGroup (median of 4) · each

1 Oct 31, 2025−4.45%
Resultsgroup −0.2%, did not move with it
1Oct 31, 2025−4.45%
ResultsFirst close after the Oct 31 results filing
−0.2% did not move with itABT −0.8 · MRK −0.3 · JNJ −0.1 · LLY +2.2
2 Nov 11, 2025+2.95%
Before our storiesgroup +2.6%, moved with ABBV
2Nov 11, 2025+2.95%
Before our stories
+2.6% moved with ABBVMRK +4.8 · JNJ +2.9 · LLY +2.3 · ABT +0.9
3 Nov 12, 2025+3.58%
Before our storiesgroup +1.0%, did not move with it
3Nov 12, 2025+3.58%
Before our stories
+1.0% did not move with itLLY +3.0 · ABT +1.4 · MRK +0.6 · JNJ +0.3
4 Nov 21, 2025+2.98%
Before our storiesgroup +2.3%, moved with ABBV
4Nov 21, 2025+2.98%
Before our stories
+2.3% moved with ABBVABT +3.3 · MRK +2.9 · LLY +1.6 · JNJ +0.4
5 Nov 24, 2025−2.87%
Before our storiesgroup +1.0%, did not move with it
5Nov 24, 2025−2.87%
Before our stories
+1.0% did not move with itABT −0.7 · LLY +1.0 · JNJ +1.1 · MRK +2.7
6 Jan 5, 2026−3.98%
Before our storiesgroup −0.3%, did not move with it
6Jan 5, 2026−3.98%
Before our stories
−0.3% did not move with itLLY −3.6 · JNJ −1.5 · MRK +0.9 · ABT +1.8
7 Jan 7, 2026+4.24%
Before our storiesgroup +0.5%, did not move with it
7Jan 7, 2026+4.24%
Before our stories
+0.5% did not move with itLLY +4.1 · JNJ +1.3 · MRK −0.3 · ABT −0.6
8 Jan 8, 2026−3.98%
Before our storiesgroup −0.8%, did not move with it
8Jan 8, 2026−3.98%
Before our stories
−0.8% did not move with itLLY −2.1 · JNJ −0.8 · ABT −0.7 · MRK +2.2
9 Feb 4, 2026−3.79%
Resultsgroup +1.4%, did not move with it
9Feb 4, 2026−3.79%
ResultsFirst close after the Feb 4 results filing
+1.4% did not move with itABT −0.8 · JNJ +0.6 · MRK +2.1 · LLY +10.3
10 Feb 12, 2026+2.99%
Before our storiesgroup +0.7%, did not move with it
10Feb 12, 2026+2.99%
Before our stories
+0.7% did not move with itLLY +2.3 · JNJ +1.5 · MRK −0.1 · ABT −1.9
11 Feb 27, 2026+3.29%
Before our storiesgroup +2.5%, moved with ABBV
11Feb 27, 2026+3.29%
Before our stories
+2.5% moved with ABBVMRK +3.8 · LLY +2.9 · JNJ +2.0 · ABT +0.1
12 Mar 18, 2026−5.20%
Before our storiesgroup −1.3%, did not move with it
12Mar 18, 2026−5.20%
Before our stories
−1.3% did not move with itABT −2.0 · LLY −1.3 · MRK −1.2 · JNJ −0.3
13 Apr 2, 2026−2.86%
Before our storiesgroup −0.2%, did not move with it
13Apr 2, 2026−2.86%
Before our stories
−0.2% did not move with itLLY −2.0 · JNJ −0.4 · MRK +0.0 · ABT +0.5
14 Apr 29, 2026+3.14%
Resultsgroup −1.4%, did not move with it
14Apr 29, 2026+3.14%
ResultsFirst close after the Apr 29 results filing
−1.4% did not move with itMRK +0.8 · JNJ −0.2 · LLY −2.6 · ABT −2.7
15 Apr 30, 2026+3.64%
Before our storiesgroup +0.3%, did not move with it
15Apr 30, 2026+3.64%
Before our stories
+0.3% did not move with itLLY +9.8 · JNJ +1.1 · ABT −0.6 · MRK −1.6
16 Jun 4, 2026+3.60%
Before our storiesgroup +4.3%, moved with ABBV
16Jun 4, 2026+3.60%
Before our stories
+4.3% moved with ABBVMRK +4.8 · ABT +4.4 · LLY +4.3 · JNJ +2.2
17 Jun 22, 2026+6.25%
Nothing on ABBVgroup +0.8%, did not move with it
17Jun 22, 2026+6.25%
Nothing on ABBVNo ABBV story, brief or results filing in our record that day
+0.8% did not move with itMRK +1.4 · JNJ +1.3 · LLY +0.3 · ABT −0.7
18 Jun 25, 2026+3.51%
Nothing on ABBVgroup +2.3%, moved with ABBV
18Jun 25, 2026+3.51%
Nothing on ABBVNo ABBV story, brief or results filing in our record that day
+2.3% moved with ABBVMRK +4.0 · ABT +3.0 · JNJ +1.6 · LLY +0.9
19 Jun 26, 2026+4.20%
Nothing on ABBVgroup +3.3%, moved with ABBV
19Jun 26, 2026+4.20%
Nothing on ABBVNo ABBV story, brief or results filing in our record that day
+3.3% moved with ABBVLLY +7.1 · JNJ +4.0 · MRK +2.6 · ABT +0.9
20 Jul 2, 2026+3.99%
Nothing on ABBVgroup +3.4%, moved with ABBV
20Jul 2, 2026+3.99%
Nothing on ABBVNo ABBV story, brief or results filing in our record that day
+3.4% moved with ABBVJNJ +3.6 · ABT +3.5 · MRK +3.3 · LLY +1.9
21 Jul 16, 2026+4.21%
Nothing on ABBVgroup +2.2%, moved with ABBV
21Jul 16, 2026+4.21%
Nothing on ABBVNo ABBV story, brief or results filing in our record that day
+2.2% moved with ABBVABT +10.7 · MRK +3.3 · JNJ +1.2 · LLY +1.1
22 Aug 18, 2026+3.43%
Nothing on ABBVgroup +2.7%, moved with ABBV
22Aug 18, 2026+3.43%
Nothing on ABBVNo ABBV story, brief or results filing in our record that day
+2.7% moved with ABBVLLY +3.6 · JNJ +3.3 · ABT +2.1 · MRK −0.6
23 Sep 8, 2026−2.99%
Nothing on ABBVgroup −2.2%, moved with ABBV
23Sep 8, 2026−2.99%
Nothing on ABBVNo ABBV story, brief or results filing in our record that day
−2.2% moved with ABBVABT −2.6 · JNJ −2.2 · LLY −2.2 · MRK −1.2

A story on the same day is not a cause, and a group move is not proof either. Group: the median of LLY, JNJ, MRK and ABT that day, the largest companies in ABBV’s SEC industry; “moved with ABBV” means the same direction and at least half the size.

What’s next · results

Before the next report: what the first day after the last four did

Six trading days after each results filing (SEC 8-K, Item 2.02). ABBV reports during the trading day, so day 1 is that day’s close. Each time, day 6 ended on the same side as day 1.

Reported Oct 31, 2025

day 1−4.45%day 6−3.96%

Reported Feb 4, 2026

day 1−3.79%day 6−2.11%

Reported Apr 29, 2026

day 1+3.14%day 6+3.71%

Reported Jul 31, 2026

day 1−2.51%day 6−4.42%

Next report: expected late OctoberEstimated from the dates of its last four results filings. Not announced. Since the Jul 31 report: +3.24%. Four reports is a small sample.

Every report since 2024 →

Each line is ABBV’s close against its close before the filing, on licensed end-of-day closes. What happened after each report, not a forecast; a move on the day is not a cause.

The numbers · FY2025, filed

SEC EDGAR

Market cap$464.4B

Revenue$61.2B+8.60%

Net income$4.2B

EPS, diluted$2.36−1.30%

Operating margin24.6%

Return on equity-130.9%

Debt / equity-19.98

All filed figures

Snapshot

SEC EDGAR · FY 2025-12-31

SectorHealthcare

Market Cap$464.4B

Enterprise Value$523.7B

Income$4.2B

Sales$61.2B

Book/sh$-1.83

Cash/sh$2.96

Dividend TTM$6.65

Payout276%

Employees—

IPO—

Quick Ratio0.56

Current Ratio0.67

Debt/Eq-19.98

EPS (ttm)$2.36

EPS this Y-1.3%

EPS past 3/5Y-29.1%

Sales past 3/5Y1.8%

EPS Y/Y TTM-1.3%

Sales Y/Y TTM8.6%

Shs Outstand1.77B

ROA3.2%

ROE-130.9%

ROIC17.3%

Gross Margin—

Oper. Margin24.6%

Profit Margin6.9%

Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.

Revenue by fiscal year

$56.2B

FY21

$58.1B

FY22

$54.3B

FY23

$56.3B

FY24

$61.2B

FY25

Operating leverage — margins

GrossOperatingNet

Financials, annual · income and cash flowSEC EDGAR · open ▸

Financials — annual

SEC EDGAR · last 5 FY · tap a row to explain it

USD	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$56.2B	$58.1B	$54.3B	$56.3B	$61.2B
Gross Profit	—	—	—	—	—
Operating Income	$17.9B	$18.1B	$12.8B	$9.1B	$15.1B
Net Income	$11.5B	$11.8B	$4.9B	$4.3B	$4.2B
Diluted EPS	$6.45	$6.63	$2.72	$2.39	$2.36
Operating Cash Flow	$22.8B	$24.9B	$22.8B	$18.8B	$19.0B
Free Cash Flow	$22.0B	$24.2B	$22.1B	$17.8B	$17.8B

Same industry

ABBV against four drug peers, a year at 100

ABBV is up 15.3% in a year. Merck is up 62.3%, Eli Lilly 37.2% and Johnson & Johnson 32.6%. Of these four, only Abbott (−24.5%) did less. Weekly closes, Oct 10, 2025 = 100, on a log scale, so the same percentage move is the same height on every line.

Share this chart

ABBV +15.3%. Merck +62.3%, Eli Lilly +37.2%, Johnson & Johnson +32.6%, Abbott −24.5%. Weekly closes, Oct 10, 2025 = 100, log scale.

Share this chart

End-of-day closes (Databento EOD), the last close of each week. The four peers are the largest US-listed companies by market value in ABBV’s SEC industry (Pharmaceutical Preparations) with a year of closes. It shows what the closes did; a move here is not a cause, a forecast or a call.

Same industry

In the screener →

LLY$1.08T JNJ$617.0B MRK$356.0B ABT$168.7B PFE$158.5B VRTX$127.9B BMY$124.9B REGN$79.8B

Follow the news. Track the move.

ABBV story timeline

Company updates and connected market context, with the dated price move attached.

Stories

Direct

Sector context/Earnings

Sep 3

AbbVie's etentamig shows 74% response rate and 60% risk reduction in Phase 3 myeloma trial

AbbVie said its Phase 3 CERVINO trial showed investigational multiple-myeloma therapy etentamig delivered a 74% objective response rate and cut the risk of progression or death by 60% versus investigator-selected standard therapies. The result strengthens AbbVie’s oncology pipeline, but the commercial read still depends on regulatory review, durability data and the eventual treatment positioning.

Since story

+2.5%

2026-09-03 → 2026-10-06

PR Newswire · 33d ago

View both sides →

Sector context/Market context